Overview

Montelukast in Acute RSV Bronchiolitis

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

There is evidence of inflammatory mechanisms in RSV bronchiolitis with increased cysteinyl-leukotrienes (cys-LT). Recently, specific cys-LT receptor antagonists - montelukast (Singulair©) approved for use in infants as granule sachets, have become available. We evaluated the effect of Singulair© on clinical progress and on cytokine profiles in the acute phase of RSV bronchiolitis.

Phase:

N/A

Details

Lead Sponsor:

Ziv Hospital

Collaborator:

Wolfson Medical Center

Treatments:

Montelukast